prikaz prve stranice dokumenta Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
  Download
PDF 726.75 KB
Professional paper - Professional paper
Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
Clinical Cardiology, 44 (2021), 8; 1177-1182. https://doi.org/10.1002/clc.23681
Željkovic, Ivan; Brusich, Sandro; Scherr, Daniel; Velagić, Vedran; Traykov, Vassil; Pernat, Andrej; Anić, Ante; Szavits Nossan, Janko; Jan, Matevz; Bakotić, Zoran; Pezo Nikolić, Borka; Radeljić, Vjekoslav; Bojko, Ana; Benko, Ivica; Manola, Šime; Pavlović, Nikola More authors...

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Željkovic, I., Brusich, S., Scherr, D., Velagić, V., Traykov, V., Pernat, A. ... Pavlović, N. (2021). Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Clinical Cardiology, 44. (8), 1177-1182. doi: 10.1002/clc.23681

Željkovic, Ivan, et al. "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy." Clinical Cardiology, vol. 44, no. 8, 2021, pp. 1177-1182. https://doi.org/10.1002/clc.23681

Željkovic, Ivan, Sandro Brusich, Daniel Scherr, Vedran Velagić, Vassil Traykov, Andrej Pernat, Ante Anić, et al. "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy." Clinical Cardiology 44, no. 8 (2021): 1177-1182. https://doi.org/10.1002/clc.23681

Željkovic, I., et al. (2021) 'Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy', Clinical Cardiology, 44(8), pp. 1177-1182. doi: 10.1002/clc.23681

Željkovic I, Brusich S, Scherr D, Velagić V, Traykov V, Pernat A, and sur.. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Clinical Cardiology [Internet]. 2021 July [cited 2024 December 02];44(8):1177-1182. doi: 10.1002/clc.23681

I. Željkovic, et al., "Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy", Clinical Cardiology, vol. 44, no. 8, pp. 1177-1182, July 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:626330. [Accessed: 02 December 2024]

Metadata
Title (english)Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
AuthorIvan Željkovic
AuthorSandro Brusich
AuthorDaniel Scherr
AuthorVedran Velagić
AuthorVassil Traykov
AuthorAndrej Pernat
AuthorAnte Anić
AuthorJanko Szavits Nossan
AuthorMatevz Jan
AuthorZoran Bakotić
AuthorBorka Pezo Nikolić
AuthorVjekoslav Radeljić
AuthorAna Bojko
AuthorIvica Benko
AuthorŠime Manola
AuthorNikola Pavlović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Periprocedural pulmonary vein isolation (PVI) anticoagulation requires balancing between bleeding and thromboembolic risk. Intraprocedural anticoagulation is monitored by activated clotting time (ACT) with target value >300 s, and there are no guidelines specifying an initial unfractionated heparin (UFH) dose. Methods: We aimed to assess differences in ACT values and UFH dosage during PVI in patients on different oral anticoagulants. We conducted an international, multi-center, registry-based study. Consecutive patients with atrial fibrillation (AF) undergoing PVI, on uninterrupted anticoagulation therapy, were analyzed. Before transseptal puncture, UFH bolus of 100 IU/kg was administered regardless of the anticoagulation drug. Results: Total of 873 patients were included (median age 61 years, IQR 53-66; female 30%). There were 248, 248, 189, 188 patients on warfarin, dabigatran, rivaroxaban, and apixaban, respectively. Mean initial ACT was 257 ± 50 s, mean overall ACT 295 ± 45 s and total UFH dose 158 ± 60 IU/kg. Patients who were receiving warfarin and dabigatran compared to patients receiving rivaroxaban and apixaban had: (i) significantly higher initial ACT values (262 ± 57 and 270 ± 48 vs. 248 ± 42 and 241 ± 44 s, p < .001), (ii) significantly higher ACT throughout PVI (309 ± 46 and 306 ± 44 vs. 282 ± 37 and 272 ± 42 s, p < .001), and (iii) needed lower UFH dose during PVI (140 ± 39 and 157 ± 71 vs. 171 ± 52 and 172 ± 70 IU/kg). Conclusion: There are significant differences in ACT values and UFH dose during PVI in patients receiving different anticoagulants. Patients on warfarin and dabigatran had higher initial and overall ACT values and needed lower UFH dose to achieve adequate anticoagulation during PVI than patients on rivaroxaban and apixaban.
Keywords (english)
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleClinical Cardiology
Numberingvol. 44, no. 8, pp. 1177-1182
p-ISSN0160-9289
e-ISSN1932-8737
DOIhttps://doi.org/10.1002/clc.23681
URN:NBNurn:nbn:hr:184:626330
Publication2021-07
Document URLhttps://onlinelibrary.wiley.com/doi/10.1002/clc.23681
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-10-26 11:43:37